FTSE MIB
34.503,68 -321,33 (-0,92%) Dow Jones
39.806,77 -196,82 (-0,49%) Nasdaq
16.794,88 +108,91 (+0,65%) Nikkei 225
38.946,93 -122,75 (-0,31%) Petrolio
79,16 -0,64 (-0,80%) Bitcoin EUR
65.334,51 +3.785,92 (+6,15%)
TLSA May 2024 5.000 put
| Chiusura precedente | 5,0000 |
| Aperto | 5,0000 |
| Denaro | 1,8500 |
| Lettera | 4,8000 |
| Prezzo d'esercizio | 5,00 |
| Scadenza | 2024-05-17 |
| Min-Max giorno | 1,8000 - 5,0000 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | N/D |
GlobeNewswireTiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab
Numeric improvements were seen across key multiple sclerosis measures, including the Modified Fatigue Impact Scale, Expanded Disability Status Scale, Timed 25-Foot Walk test, Pyramidal Scores and NeuroQoL™ Fatigue scores.Data was presented at ECTRIMS (39th Congress of the European Committee for Treatment and Research of Multiple Sclerosis) on October 11, 2023 NEW YORK, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology compan
GlobeNewswireTiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)
Figure 1 Six-Month PET Scan Five out of six patients in FDA authorized Expanded Access Program are showing a qualitative reduction in microglia activation (a key biomarker being observed)Foralumab to advance into Phase 2 human clinical trials using the world’s only fully human intranasal anti-CD3 monoclonal antibodyPhase 2 trial screening for na-SPMS to begin in November 2023 NEW YORK, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a bio
- GlobeNewswire
Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress
Late-breaking poster to be presented titled: “Treatment Of Six Non-Active Secondary Progressive MS With Nasal Anti-CD3 Monoclonal Antibody (Foralumab): Safety, Biomarker, And Disability Outcomes” NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced a late breaking poster titled, “Treatment Of Six Non-Active Se
